Planegg - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced its participation at three upcoming business development and scientific conferences:
BIO International Convention
Date: 19 - 22 June 2017
Location: San Diego, USA
FORUM Science & Health
Date: 5 - 6 July 2017
Location: Fürstenfeldbruck, Germany
Dr. Dr. Olav Zilian, Senior Vice President Corporate Development, will hold a company presentation on 6 July.
Date: 28 August - 1 September 2017
Location: Boston, USA
Prof. Dolores Schendel, CEO and CSO of Medigene, will give an oral presentation on 1 September at 11.30 AM on the topic: " High-Throughput Functional Screening of Neoantigens for Vaccines and TCR-Based Adoptive T Cell Therapies".
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.